The record
Written from the 1 report below. Nothing here is unsourced.
- Zydus Life shares rose 2% after positive analyst comments on its ALS drug candidate Usnoflast.
- Global brokerage Bernstein kept an Outperform rating on Zydus Life.
- Novartis has exited its ALS drug, reducing competition for Zydus's candidate.
- Key clinical data for Usnoflast is still awaited.
- A weaker competitive field could improve the drug's commercial prospects if the trials succeed.
What to watch next
- Release of key clinical trial data for Usnoflast
- Any further competitor exits or entries in the ALS drug market
- Whether Bernstein and other analysts maintain their ratings after the data
Coverage1
1 report
English national1
All filed from India
Named India · Usnoflast · Zydus Life Sciences · Bernstein · Novartis
The 1 report is listed beside the record.
Ask this story
Answers cite the reports above, or say they can't.